Search Medical Condition
Please enter condition
Please choose location

East Setauket, New York Clinical Trials

A listing of East Setauket, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (174) clinical trials

Tolerability Safety and Activity of SRX246 in Irritable Subjects With Huntington's Disease

SRX246 is a first-in-class vasopressin 1a (V1a) receptor antagonist that crosses the blood-brain barrier following oral administration. The molecule exhibits high affinity and high selectivity for its target receptor. Preclinical pharmacology studies have demonstrated significant CNS effects in models of irritability, including impulsive aggression, depression, and anxiety. In an experimental ...

Phase

0.0 miles

Learn More »

Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).

Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients.

Phase

0.0 miles

Learn More »

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

This is a non-randomized, open-label, Phase 1/2 trial of VT-464 in patients with AR (+) TNBC or ER (+)/HER2 normal unresectable locally advanced MBC. . Phase 2 is an open-label, multi-center study and divided into parallel cohorts: AR (+) TNBC and ER (+) BC patients at the RP2D confirmed/established in ...

Phase

0.0 miles

Learn More »

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

This is a Phase 1/2 study of seviteronel in subjects with castration-resistant prostate cancer (CRPC). Phase 1 was a dose-escalation study enrolling subjects with CRPC that were either "treatment naïve" (not treated with previous abiraterone or enzalutamide), or treated with one or more of the following: abiraterone, enzalutamide, or chemotherapy. ...

Phase

0.0 miles

Learn More »

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

According to the cancer stem cell (CSC) model, tumors are initiated and maintained by a cellular subcomponent that displays stem cell properties. These properties include self-renewal, which drives tumorigenesis, and differentiation (albeit aberrant), which contributes to tumor cellular heterogeneity. The existence of CSCs has been described in a variety of ...

Phase

0.0 miles

Learn More »

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status. Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus nab-paclitaxel ...

Phase

0.0 miles

Learn More »

Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer

This is a phase 2, open-label, multicenter study to evaluate the efficacy and tolerability of poziotinib in approximately 70 patients with HER2-positive metastatic breast cancer who have received at least 2 prior HER2-directed treatment regimens. Each treatment cycle will be 21 days in duration. During each 21-day cycle, patients who ...

Phase

0.0 miles

Learn More »